Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.

Trial Details

NCT ID
NCT05620732
Phase
NA
Sponsor
Shenzhen University General Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Claudin18.2 CAR-T cells
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Age 18-75 (≥ 18, ≤ 75), regardless of gender;
  • Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
  • Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer …
  • According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →